PCOS (Polycystic Ovary Syndrome)
The most common hormonal condition in women, and one of the most misnamed
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
PCOS is a well-characterized endocrine disorder with international diagnostic and management consensus. The 2003 Rotterdam criteria (any 2 of 3: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology) and the 2023 International Evidence-Based Guideline (77 evidence-based and 54 consensus recommendations, endorsed by the Endocrine Society, ESHRE, ASRM, ESE and others) establish diagnosis and first-line care: lifestyle, combined oral contraceptive for cycle and androgen control, metformin for metabolic features, and letrozole first-line for anovulatory infertility. Inositol sits lower on the evidence ladder (grade 2-3), with a 2024 systematic review informing the guideline finding possible cycle and metabolic benefit but limited certainty.
Reference only. Not medical advice.
What can go wrong
PCOS raises long-term risk of type 2 diabetes, and prolonged absence of periods can affect the uterine lining, so it needs ongoing medical care rather than self-management alone. Emotional effects, including depression and body-image distress, are common and deserve support.
This is something to take to a clinician. The Atlas can tell you what is known about pcos (polycystic ovary syndrome) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
PCOS affects up to one in ten women and is a leading cause of infertility, yet its name is misleading, since the cysts are not really cysts and many women with it have none.
How it works
The core disturbance involves hormones that regulate the ovaries, higher levels of male-type hormones (androgens), and, in many women, insulin resistance that drives the ovaries to make even more androgen. The 'cysts' seen on ultrasound are actually many small follicles that stall rather than release an egg, which is why the name is misleading.
Safety in detail
PCOS is a clinical diagnosis that requires a qualified provider, since the Rotterdam criteria call for excluding conditions that mimic it, such as thyroid disorders, hyperprolactinemia, and non-classic congenital adrenal hyperplasia. It raises long-term risk of type 2 diabetes, and prolonged absence of periods can affect the uterine lining and is associated with higher endometrial cancer risk, so unopposed long gaps between periods need medical assessment rather than self-management. Anxiety, depression, and body-image distress are common and deserve support. Marketed 'PCOS support' supplements are not a substitute for evaluation; discuss any supplement, including inositol, with a provider.
What people get wrong
Often saidPCOS means your ovaries are full of cysts.
ActuallyThe follicles seen on ultrasound are not true cysts, and many women who have PCOS do not have them at all.
Often saidPCOS just means you cannot get pregnant.
ActuallyIt is a leading cause of infertility, but many women with PCOS conceive, with or without help, and it is really a lifelong metabolic and hormonal condition.
Who profits, and who pushes back
Endocrine and gynecology guidelines
Define PCOS by cycle, androgen, and ovarian criteria and recommend lifestyle plus targeted medication.
Inositol researchers
Report that inositol supplements may help cycles and metabolism in some women, with growing but not definitive evidence.
Supplement sellers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market broad 'PCOS support' formulas, most without solid evidence.
Where the research comes from
Most of the published research on this comes from one place. 95% of it is from Global. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Global | 95% |
How we got here
Women with irregular cycles, excess hair, and infertility are described across the historical record, but the modern syndrome was formally reported by the American gynecologists Irving Stein and Michael Leventhal in 1935, so it was long called Stein-Leventhal syndrome. Diagnostic definitions shifted from the 1990 NIH criteria to the broader 2003 Rotterdam consensus criteria, which the Androgen Excess and PCOS Society refined in 2006 to foreground androgen excess, and the 2018 and 2023 International Evidence-Based Guidelines standardized care and added anti-Mullerian hormone as an alternative to ultrasound. In 2026 a global consensus process led by Monash University and the Androgen Excess and PCOS Society, involving 56 organizations and more than 22,000 survey responses, renamed the condition Polyendocrine Metabolic Ovarian Syndrome (PMOS), on the documented finding that the 'cysts' are stalled follicles rather than true cysts and that the old name obscured its endocrine and metabolic nature.
Named after two doctors in 1935 and long defined by its ovarian appearance, PCOS has been reframed over the last few decades as a metabolic and hormonal condition affecting the whole body, which changed how it is treated.
- Historical recordIrregular cycles and excess hair described across cultures
- 1935Stein and Leventhal describe the syndrome
- 1990s-2000sDiagnostic criteria formalized and debated
- 2010s-2020sReframed around insulin resistance and whole-body health
How it is understood
PCOS is now understood as a whole-body hormonal and metabolic condition rather than an ovary problem. It commonly involves irregular or absent periods, higher androgen levels causing acne or excess hair, and often insulin resistance, and it raises long-term risk of type 2 diabetes.
At a glance
- How common
- Up to about one in ten women
- First described
- Stein and Leventhal, 1935
- Often involves
- Insulin resistance
- Long-term risk
- Type 2 diabetes
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about PCOS (Polycystic Ovary Syndrome). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
PCOS diagnosis follows the 2003 Rotterdam criteria requiring any two of three: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries; the 2023 guideline adds AMH as an alternative to ultrasound.
The 2023 guideline names combined oral contraceptives as first-line for menstrual irregularity and hyperandrogenism, metformin for metabolic features, and letrozole as first-line for anovulatory infertility; PCOS affects roughly 10-13 percent of reproductive-age women.
The 2023 International Evidence-Based Guideline provides 77 evidence-based and 54 consensus recommendations and is endorsed by multiple international societies to standardize PCOS care.
Full guideline summary detailing diagnostic criteria, adolescent-specific rules, and evidence-based management pathways.
Inositol for PCOS shows possible benefit for cycles and metabolic measures but limited certainty of evidence; systematic review conducted to inform the 2023 guideline update.
Inositol improves the likelihood of a regular menstrual cycle versus placebo and is non-inferior to metformin on that outcome in pooled RCTs.
In 2026 a multistep global consensus renamed PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS), on the finding that there is no increase in abnormal ovarian cysts, confirming the old name is a misnomer.
The renaming to PMOS emerged from a multistep global consensus process involving 56 organizations and more than 22,000 survey responses, published in The Lancet.
The Androgen Excess and PCOS Society is the international body focused on androgen excess disorders including PCOS, whose leadership co-led the diagnostic refinements and the renaming process.
AMH measurement is validated as an alternative to ultrasound for identifying polycystic ovarian morphology within the diagnostic criteria.